Literature DB >> 36177870

Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022.

Noam Barda1,2,3, Michal Canetti4,5, Mayan Gilboa4,5, Victoria Indenboim5,6, Keren Asraf5,7, Yael Weiss-Ottolenghi4,5, Sharon Amit5,8, Daniel Zibly4, Ram Doolman5,6, Ella Mendelson5,7, Dror Harats5,9, Laurence S Freedman10, Yitshak Kreiss5,9, Yaniv Lustig5,6, Gili Regev-Yochay4,5.   

Abstract

We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27-1.97) in Spikevax and 1.16-fold (95% CI: 0.98-1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62-1.09) and Comirnaty (0.86; 95% CI: 0.65-1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13-0.62) and 0.51 (95% CI: 0.27-0.96), respectively.

Entities:  

Keywords:  BNT162b2; COVID-19; boosters; immunogenicity; mRNA1273; vaccine efficacy

Mesh：

Substances：

Year:  2022        PMID： 36177870      PMCID： PMC9524052          DOI： 10.2807/1560-7917.ES.2022.27.39.2200701

Source DB:  PubMed          Journal:  Euro Surveill        ISSN： 1025-496X


  12 in total

1.  Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose.

Authors:  Yaniv Lustig; Tal Gonen; Lilac Meltzer; Mayan Gilboa; Victoria Indenbaum; Carmit Cohen; Sharon Amit; Hanaa Jaber; Ram Doolman; Keren Asraf; Carmit Rubin; Ronen Fluss; Ella Mendelson; Laurence Freedman; Gili Regev-Yochay; Yitshak Kreiss
Journal:  Nat Immunol       Date:  2022-05-09       Impact factor: 31.250

2.  Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.

Authors:  Hung Fu Tseng; Bradley K Ackerson; Yi Luo; Lina S Sy; Carla A Talarico; Yun Tian; Katia J Bruxvoort; Julia E Tubert; Ana Florea; Jennifer H Ku; Gina S Lee; Soon Kyu Choi; Harpreet S Takhar; Michael Aragones; Lei Qian
Journal:  Nat Med       Date:  2022-02-21       Impact factor: 87.241

3.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Authors:  Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks
Journal:  N Engl J Med       Date:  2020-12-30       Impact factor: 91.245

4.  Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.

Authors:  Eric J Haas; Frederick J Angulo; John M McLaughlin; Emilia Anis; Shepherd R Singer; Farid Khan; Nati Brooks; Meir Smaja; Gabriel Mircus; Kaijie Pan; Jo Southern; David L Swerdlow; Luis Jodar; Yeheskel Levy; Sharon Alroy-Preis
Journal:  Lancet       Date:  2021-05-05       Impact factor: 79.321

5.  Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.

Authors:  Noam Barda; Noa Dagan; Cyrille Cohen; Miguel A Hernán; Marc Lipsitch; Isaac S Kohane; Ben Y Reis; Ran D Balicer
Journal:  Lancet       Date:  2021-10-29       Impact factor: 79.321

6.  Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.

Authors:  Einav G Levin; Yaniv Lustig; Carmit Cohen; Ronen Fluss; Victoria Indenbaum; Sharon Amit; Ram Doolman; Keren Asraf; Ella Mendelson; Arnona Ziv; Carmit Rubin; Laurence Freedman; Yitshak Kreiss; Gili Regev-Yochay
Journal:  N Engl J Med       Date:  2021-10-06       Impact factor: 91.245

7.  Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.

Authors:  Jill M Ferdinands; Suchitra Rao; Brian E Dixon; Patrick K Mitchell; Malini B DeSilva; Stephanie A Irving; Ned Lewis; Karthik Natarajan; Edward Stenehjem; Shaun J Grannis; Jungmi Han; Charlene McEvoy; Toan C Ong; Allison L Naleway; Sarah E Reese; Peter J Embi; Kristin Dascomb; Nicola P Klein; Eric P Griggs; Deepika Konatham; Anupam B Kharbanda; Duck-Hye Yang; William F Fadel; Nancy Grisel; Kristin Goddard; Palak Patel; I-Chia Liao; Rebecca Birch; Nimish R Valvi; Sue Reynolds; Julie Arndorfer; Ousseny Zerbo; Monica Dickerson; Kempapura Murthy; Jeremiah Williams; Catherine H Bozio; Lenee Blanton; Jennifer R Verani; Stephanie J Schrag; Alexandra F Dalton; Mehiret H Wondimu; Ruth Link-Gelles; Eduardo Azziz-Baumgartner; Michelle A Barron; Manjusha Gaglani; Mark G Thompson; Bruce Fireman
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2022-02-18       Impact factor: 17.586

8.  Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron.

Authors:  Gili Regev-Yochay; Tal Gonen; Mayan Gilboa; Michal Mandelboim; Victoria Indenbaum; Sharon Amit; Lilac Meltzer; Keren Asraf; Carmit Cohen; Ronen Fluss; Asaf Biber; Ital Nemet; Limor Kliker; Gili Joseph; Ram Doolman; Ella Mendelson; Laurence S Freedman; Dror Harats; Yitshak Kreiss; Yaniv Lustig
Journal:  N Engl J Med       Date:  2022-03-16       Impact factor: 91.245

9.  Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.

Authors:  Laurence Chu; Keith Vrbicky; David Montefiori; Wenmei Huang; Biliana Nestorova; Ying Chang; Andrea Carfi; Darin K Edwards; Judy Oestreicher; Holly Legault; Frank J Dutko; Bethany Girard; Rolando Pajon; Jacqueline M Miller; Rituparna Das; Brett Leav; Roderick McPhee
Journal:  Nat Med       Date:  2022-03-03       Impact factor: 87.241

10.  Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.

Authors:  Salim S Abdool Karim; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2021-12-03       Impact factor: 202.731
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.